Systemic Treatment of Prostate Cancer.
Horwich, Alan.
Systemic Treatment of Prostate Cancer. [E-Book] - Oxford : OUP Oxford, 2010. - 1 online resource (102 pages) - Oxford Oncology Library . - Oxford oncology library. .
Biological principles of hormone therapy -- PSA as a marker of progression and response in advanced prostate cancer -- Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer -- Systemic treatment of recurrence after local therapies -- First-line hormone therapy for metastatic prostate cancer -- Second- and third-line hormone therapies -- Chemotherapy for metastatic prostate cancer -- Role of bisphosphonates in the systemic treatment of prostate cancer -- Systemic isotope therapy of bone metastasis -- Biological targets and new drug development for prostate cancer.
Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r.
English.
9780191575815 019157581X 1283348330 9781283348331 0199561427 9780199561421
Prostate--Cancer--Diagnosis.
Prostate--Cancer--Treatment.
Prostate--Diseases.
Generative organs, Male--Diseases.
Genitourinary organs--Diseases.
Diseases.
Genital Neoplasms, Male
Prostatic Diseases
Genital Diseases, Male
Urogenital Neoplasms
Male Urogenital Diseases
Neoplasms by Site
Disease
Neoplasms
Prostatic Neoplasms
Female Urogenital Diseases
Systemic Treatment of Prostate Cancer. [E-Book] - Oxford : OUP Oxford, 2010. - 1 online resource (102 pages) - Oxford Oncology Library . - Oxford oncology library. .
Biological principles of hormone therapy -- PSA as a marker of progression and response in advanced prostate cancer -- Neo-adjuvant and adjuvant hormone therapy for high-risk localized prostate cancer -- Systemic treatment of recurrence after local therapies -- First-line hormone therapy for metastatic prostate cancer -- Second- and third-line hormone therapies -- Chemotherapy for metastatic prostate cancer -- Role of bisphosphonates in the systemic treatment of prostate cancer -- Systemic isotope therapy of bone metastasis -- Biological targets and new drug development for prostate cancer.
Prostate cancer is one of the commonest cancers in men in the western world, and the prevalence is rising currently due to improvements in screening and treatment. Serum PSA represents a useful marker of disease. It has frequently a long natural history, creating the opportunities for multiple sequential therapeutic interventions. For patients with high risk local disease or with metastases, endocrine therapy is central to management. Hormone ablation has long been the mainstay ofendocrine therapy in this group of patients, though anti-androgens, oestrogens and corticosteroids can also cause r.
English.
9780191575815 019157581X 1283348330 9781283348331 0199561427 9780199561421
Prostate--Cancer--Diagnosis.
Prostate--Cancer--Treatment.
Prostate--Diseases.
Generative organs, Male--Diseases.
Genitourinary organs--Diseases.
Diseases.
Genital Neoplasms, Male
Prostatic Diseases
Genital Diseases, Male
Urogenital Neoplasms
Male Urogenital Diseases
Neoplasms by Site
Disease
Neoplasms
Prostatic Neoplasms
Female Urogenital Diseases